AngioDynamics (NASDAQ:ANGO) SVP Sells $344,006.40 in Stock

AngioDynamics, Inc. (NASDAQ:ANGO) SVP Warren Nighan, Jr. sold 23,370 shares of the stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $14.72, for a total transaction of $344,006.40. Following the completion of the transaction, the senior vice president owned 64,745 shares of the company’s stock, valued at approximately $953,046.40. The trade was a 26.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

AngioDynamics Price Performance

Shares of NASDAQ ANGO opened at $14.79 on Monday. AngioDynamics, Inc. has a 1 year low of $8.36 and a 1 year high of $15.19. The firm has a 50-day moving average of $12.81 and a 200 day moving average of $11.51. The stock has a market cap of $611.27 million, a P/E ratio of -17.00 and a beta of 0.33.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.04. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. The business had revenue of $86.61 million for the quarter, compared to analysts’ expectations of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. Research analysts expect that AngioDynamics, Inc. will post -0.27 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have issued reports on ANGO shares. Zacks Research cut AngioDynamics from a “hold” rating to a “strong sell” rating in a research note on Thursday, July 16th. Canaccord Genuity Group increased their target price on AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Freedom Capital upgraded AngioDynamics to a “strong-buy” rating in a report on Monday, April 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a research report on Friday, July 17th. Finally, HC Wainwright upped their price target on shares of AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $19.50.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Franklin Resources Inc. boosted its position in shares of AngioDynamics by 2.3% during the fourth quarter. Franklin Resources Inc. now owns 48,359 shares of the medical instruments supplier’s stock valued at $621,000 after buying an additional 1,076 shares during the last quarter. Farther Finance Advisors LLC increased its holdings in AngioDynamics by 146.4% in the 4th quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 1,199 shares in the last quarter. Deutsche Bank AG raised its position in AngioDynamics by 5.9% in the 4th quarter. Deutsche Bank AG now owns 35,584 shares of the medical instruments supplier’s stock worth $457,000 after buying an additional 1,992 shares during the last quarter. Kemnay Advisory Services Inc. bought a new position in AngioDynamics during the 4th quarter valued at about $27,000. Finally, Price T Rowe Associates Inc. MD lifted its stake in AngioDynamics by 5.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 44,298 shares of the medical instruments supplier’s stock valued at $569,000 after acquiring an additional 2,263 shares during the period. Hedge funds and other institutional investors own 89.43% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.